NYSCF Global Stem Cell Array
Developed by NYSCF scientists and engineers, the array enables research to functionalize human genetics, merging data from the human genome with our own biology to accelerate discovery of new therapies.
This pioneering automation technology allows NYSCF to:
- Standardize and scale out production of induced pluripotent stem (iPS) cells, which are stem cells made from an individual’s own skin or blood cells.
- Study iPS cells from thousands of patients, reflecting the genetic diversity of the global population and enabling scientists to detect patterns that are only discernable when examining a large population of patients, and which show how different genetic mutations impact individual disease symptoms.
- Conduct clinical trials in a petri dish using the actual affected human cell types affected by disease and from patients, testing drugs and therapies directly on human cells for precision drug development.
- Develop more effective, safer, and less expensive new drugs to target the causes of disease, by factoring in genetic differences during the development process. This revolutionary approach will help “de-risk” projects that pharmaceutical companies would typically avoid.
In 2015, NYSCF scientists published a paper describing the NYSCF Array in the journal Nature Methods. Read the publication and learn more about the NYSCF Array’s capabilities and the validation of NYSCF-generated stem cells lines in the press release.
If you are interested in collaborative opportunities using the NYSCF Global Stem Cell Array, please contact email@example.com.